Elyssa Benedikt Email & Phone Number

- Commercial lead on partnered hemophilia drug with plans to enter Phase 3 early 2017- Collaborated closely with partner in defining early brand strategy and commercial requirements, refining TPP, engaging with medical education, patient advocacy, KOL management- Reviewed 2016 investment plan and budgets; led business planning process for 2017 with partner- Provided input into strategic and tactical discussions- Developed forecast and valuation to support internal decision making for opt-in for co-commercialization in N. America and Western Europe, presenting to Sanofi senior leadership (including CEO)

- Commercial lead on four ophthalmology programs, including three gene therapies for rare ocular diseases (Phase I/II)- Prepared forecast, supported valuation and and due diligence on $300M acquisition of CAPRELSA- Prepared commercial assessments for internal pipeline programs to support investment decisions- Conducted KOL interviews, prepared forecast and initial assessment of Alnylam AT3 for opt-in- Spearheaded prioritization project, working with BD, to help shape strategic direction of re-organized rare disease unit, by coordinating cross-functional team (R&D, medical, commercial) to identify and prioritize internal and external opportunities and assisting with deep-dive assessments

- Prepared assessments of new opportunities for leadership approval. Resulted in offering 6 non-binding offers - Coordinated due diligence (R&D, clinical, IP, manufacturing, etc.) for several opportunities

- Developed 2014 brand plan and managed about $1.0 million budget for Genzyme’s unbranded educational website for HCPs and consumers, including content development, KOL engagement, and promotion - Coordinated promotional campaign via PeerDirect, including email and direct mail promotion - Helped train about one hundred new Aubagio speakers, coordinating cross-functional team- Assisted in coordination, material development, and day-of support for large patient outreach programs, with hundreds of patients attending

OverviewThe Biomedical Enterprise Program (BEP) is jointly administered by the Harvard-MIT Division of Health Sciences and Technology (HST) and the MIT Sloan School of Management. The program exposes students to an integrated curriculum focused on the complex process of product development and commercialization in the health care industry. BEP rigorously prepares tomorrow's entrepreneurs and managers to transform scientific discovery into patient-oriented, commercially successful products and services. Graduates go on to become entrepreneurial leaders trained to identify and manage scientific and clinical research and financial opportunities that build successful innovative biomedical businesses.

- Analyzed analog development programs to recommend strategy for critical project; analysiswas referenced in strategy meetings and distributed to senior management including CEO

Consulting firm that developed P&R and marketing strategies for 24/25 top pharma- Managed day-to-day activities for diverse global teams on projects spanning the US, Europe, Asia and Latin America for major firms (including Novartis, J&J, Pfizer, Bayer, and AstraZeneca)- Developed marketing and pricing strategy for >15 products- Researched treatment paradigms and competitive environment for a wide range of therapeutic areas- Conducted primary research with payers, physicians, lab directors and pharmacists- Built pricing and contracting models using Excel, SPSS and discrete-choice/adaptive conjoint analysis- Developed value stories and product positioning- Supervised and trained new employees- Promoted twice within first two years in recognition of superior work and management skills

Mental Health Policy